Status: Not yet recruiting
MLS101 Study in PMDD
The goal of this clinical trial is to learn if MLS101 (psilocybin) is a possible treatment for women with Premenstrual Dysphoric Disorder (PMDD). The main question it aims to answer is: • Test the safety and tolerability of the study drug, MLS101 in premenopausal women (ages 18-50 inclusive) with PMDD.
Participants needed: 32
Trial details
Phase: Phase 1Age: 18-50Biological sex: FemaleType: InterventionalSponsor: MycoMedica Life Sciences PBCUpdated: Sep 14, 2026
Eligibility criteria
Provides informed consent for participating in the study [+9]
Currently meets DSM-5 criteria for MDD, GAD, Panic Disorder, OCD, Anorexia, Buli... [+33]